Patents by Inventor Tohru Miyazaki

Tohru Miyazaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20240360080
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: November 27, 2023
    Publication date: October 31, 2024
    Inventors: Yasushi HATTORI, Yuhei MIYANOHANA, Yuichi KAJITA, Tatsuki KOIKE, Yasutaka HOASHI, Norihito TOKUNAGA, Alexander Martin PAWLICZEK, Tsuneo ODA, Tohru MIYAZAKI, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO
  • Heterocyclic compound
    Patent number: 12091410
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: September 17, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Yasutaka Hoashi, Yasushi Hattori, Norihito Tokunaga, Tsuneo Oda, Tohru Miyazaki, Dilhumar Uyghur, Yoshiteru Ito, Kohei Takeuchi, Keisuke Imamura, Takahiro Sugimoto, Koichiro Fukuda, Yasuhisa Kohara, Rei Okamoto, Taiichi Ohra, Naoki Miyamoto, Yoshito Terao, Masanori Kawasaki
  • Heterocyclic compound
    Patent number: 12084436
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: September 10, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro Ito, Takeshi Yamamoto, Keiko Kakegawa, Hideyuki Sugiyama, Tohru Miyazaki, Yasuyoshi Arikawa, Tomohiro Okawa, Jinichi Yonemori, Osamu Kubo, Akinori Toita, Takuto Kojima, Fumiaki Kikuchi, Minoru Sasaki, Misaki Homma, Yasuhiro Imaeda, Hironobu Maezaki, Shiinobu Sasaki, Ayumu Sato, Hirotaka Kamitani, Yasutomi Asano, Hironori Kokubo, Masato Yoshikawa
  • Heterocyclic compound and application thereof
    Patent number: 12077522
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: September 3, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Koichiro Fukuda, Hiromichi Sugimoto, Kentaro Rikimaru, Yoshihiro Banno, Takahiro Matsumoto, Norihito Tokunaga, Yoshihide Tomata, Yuji Ishichi, Shogo Marui, Tsuneo Oda, Tohru Miyazaki, Yasutaka Hoashi, Yasushi Hattori, Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike
  • Heterocyclic compound
    Patent number: 12071434
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: August 27, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuhei Miyanohana, Yuichi Kajita, Tatsuki Koike, Yasutaka Hoashi, Yasushi Hattori, Norihito Tokunaga, Tsuneo Oda, Tohru Miyazaki, Dilhumar Uyghur, Yoshiteru Ito, Kohei Takeuchi, Keisuke Imamura, Takahiro Sugimoto, Koichiro Fukuda, Yasuhisa Kohara, Rei Okamoto, Taiichi Ohra, Naoki Miyamoto, Jun Chiba, Yoshito Terao, Masanori Kawasaki
  • Heterocyclic compound and use thereof
    Patent number: 11655241
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: May 23, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Oda, Yoshiteru Ito, Tohru Miyazaki, Kohei Takeuchi, Norihito Tokunaga, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura, Yuichi Kajita, Yuhei Miyanohana, Takahiro Sugimoto, Tatsuki Koike, Dilhumar Uyghur
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20230063805
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: June 22, 2022
    Publication date: March 2, 2023
    Inventors: Yuichi KAJITA, Yuhei MIYANOHANA, Tatsuki KOIKE, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • HETEROCYCLIC COMPOUND
    Publication number: 20230042358
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: December 11, 2019
    Publication date: February 9, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuhei MIYANOHANA, Yuichi KAJITA, Tatsuki KOIKE, Yasutaka HOASHI, Yasushi HATTORI, Norihito TOKUNAGA, Tsuneo ODA, Tohru MIYAZAKI, Dilhumar UYGHUR, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO, Koichiro FUKUDA, Yasuhisa KOHARA, Rei OKAMOTO, Taiichi OHRA, Naoki MIYAMOTO, Jun CHIBA, Yoshito TERAO, Masanori KAWASAKI
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20230040770
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: January 30, 2020
    Publication date: February 9, 2023
    Inventors: Yasushi HATTORI, Yuhei MIYANOHANA, Tatsuki KAJITA, Tatsuki KOIKE, Yasutaka HOASHI, Norihito TOKUNAGA, Alexander Martin PAWLICZEK, Tsuneo ODA, Tohru MIYAZAKI, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO
  • Heterocyclic compound and use thereof
    Patent number: 11440883
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: September 13, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • LIFESTYLE IMPROVEMENT SPECIFIC MEASURE PRESENTING DEVICE, LIFESTYLE IMPROVEMENT SPECIFIC MEASURE PRESENTING METHOD, RECORDING MEDIUM, AND LIFESTYLE IMPROVEMENT SPECIFIC MEASURE PRESENTING SYSTEM
    Publication number: 20220246259
    Abstract: A lifestyle improvement specific measure presenting device includes a formulating unit which formulates a lifestyle improvement strategy, which is a behavioral strategy for a user for improving a predetermined lifestyle habit of the user, on the basis of information indicating the predetermined lifestyle habit, included in a predicted result of the future health condition of the user if the predetermined lifestyle habit is improved.
    Type: Application
    Filed: April 23, 2020
    Publication date: August 4, 2022
    Applicant: NEC Solution Innovators, Ltd.
    Inventors: Hirofumi TANAKA, Toshikazu TAJIRI, Tohru MIYAZAKI
  • Heterocyclic compound and application thereof
    Patent number: 11319286
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 3, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Yuichi Kajita, Satoshi Mikami, Yuhei Miyanohana, Tatsuki Koike, Masaki Daini, Masaki Ogino, Kohei Takeuchi, Tohru Miyazaki, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • HETEROCYCLIC COMPOUND
    Publication number: 20220098180
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Application
    Filed: January 29, 2020
    Publication date: March 31, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro ITO, Takeshi YAMAMOTO, Keiko KAKEGAWA, Hideyuki SUGIYAMA, Tohru MIYAZAKI, Yasuyoshi ARIKAWA, Tomohiro OKAWA, Jinichi YONEMORI, Osamu KUBO, Akinori TOITA, Takuto KOJIMA, Fumiaki KIKUCHI, Minoru SASAKI, Misaki HOMMA, Yasuhiro IMAEDA, Hironobu MAEZAKI, Shiinobu SASAKI, Ayumu SATO, Hirotaka KAMITANI, Yasutomi ASANO, Hironori KOKUBO, Masato YOSHIKAWA
  • HETEROCYCLIC COMPOUND
    Publication number: 20220017514
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: December 11, 2019
    Publication date: January 20, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi KAJITA, Yuhei MIYANOHANA, Tatsuki KOIKE, Yasutaka HOASHI, Yasushi HATTORI, Norihito TOKUNAGA, Tsuneo ODA, Tohru MIYAZAKI, Dilhumar UYGHUR, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO, Koichiro FUKUDA, Yasuhisa KOHARA, Rei OKAMOTO, Taiichi OHRA, Naoki MIYAMOTO, Yoshito TERAO, Masanori KAWASAKI
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20210276949
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: April 23, 2021
    Publication date: September 9, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yasushi HATTORI, Yuhei MIYANOHANA, Yuichi KAJITA, Tatsuki KOIKE, Yasutaka HOASHI, Norihito TOKUNAGA, Alexander Martin PAWLICZEK, Tsuneo ODA, Tohru MIYAZAKI, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO
  • HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
    Publication number: 20210269420
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: June 27, 2019
    Publication date: September 2, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Koichiro FUKUDA, Hiromichi SUGIMOTO, Kentaro RIKIMARU, Yoshihiro BANNO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Yoshihide TOMATA, Yuji ISHICHI, Shogo MARUI, Tsuneo ODA, Tohru MIYAZAKI, Yasutaka HOASHI, Yasushi HATTORI, Yuichi KAJITA, Yuhei MIYANOHANA, Tatsuki KOIKE
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20210198240
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: June 27, 2019
    Publication date: July 1, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo ODA, Yoshiteru ITO, Tohru MIYAZAKI, Kohei TAKEUCHI, Norihito TOKUNAGA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA, Yuichi KAJITA, Yuhei MIYANOHANA, Takahiro SUGIMOTO, Tatsuki KOIKE, Dilhumar UYGHUR
  • Heterocyclic compound and use thereof
    Patent number: 11028048
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: June 8, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yasushi Hattori, Yuhei Miyanohana, Yuichi Kajita, Tatsuki Koike, Yasutaka Hoashi, Norihito Tokunaga, Alexander Martin Pawliczek, Tsuneo Oda, Tohru Miyazaki, Marilena Pira, Javier Miguelez-Ramos
  • Data transfer system, data transfer apparatus, data transfer method, and computer-readable recording medium
    Patent number: 11017029
    Abstract: A data transfer system includes a management server 1 for managing user information, browsing setting information that defines a user who can browse data, and transfer setting information that designates a transfer destination of the data, a data transfer apparatus 2 for setting, for the data, browsing authorization that allows only a specific user to browse the content of the data, based on the user information and the browsing setting information, and transferring the data for which the browsing authorization is set to the designated transfer destination based on the transfer setting information, and a data browsing apparatus 3 for determining whether or not a user has the browsing authorization that is set for the data, based on the user information, the browsing setting information, and the transfer setting information, and presenting the content of the data to the user if the user has the browsing authorization.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: May 25, 2021
    Assignee: NEC Solution Innovators, Ltd.
    Inventor: Tohru Miyazaki
  • HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
    Publication number: 20200385346
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: December 10, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Masaki OGINO, Kohei TAKEUCHI, Tohru MIYAZAKI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA